Vidastat: Four years and growing stronger

Therapharma recently celebrated the fourth anniversary of the simvastatin Vidastat, the pharmacoeconomic drug indicated for the treatment and management of dyslipidemia.

Vidastat, which became available in 2002, was one of the first drugs to be launched under the pharmacoeconomics campaign which aims to provide safe, effective and affordable drugs for the treatment of chronic diseases.

"We wanted to help as many Filipino patients by making quality cardiovascular medicines accessible and affordable to all our kababayans," said John Dumpit, Therapharma’s general manager.

Since the launching of Vidastat, prices of cholesterol-lowering medicine started going down.

Because of the astounding success of Vidastat, Therapharma will soon be a launching a new brand of amlodipine.

"I assure you dear doctors that this will happen very soon," Dumpit said.

Just like Vidastat, the new amlodipine will be priced by as much as 50 percent less than the originator brand.

With the introduction of pharmacoeconomic brands of medicine, more and more Filipino patients are clamoring for local pharmaceutical companies, especially Unilab, to provide them with effective medicines at prices which they can afford.

Aside from providing patients with effective, safe and affordable medicines, Therapharma is also set on helping other organizations in saving endangered species.

To commemorate Vidastat’s anniversary, Therapharma donated P150,000 to Haribon Foundation in support of some of its reforestation projects.